TROP2 in colorectal carcinoma: associations with histopathology, molecular phenotype, and patient prognosis
Abstract Antibody-drug conjugates (ADCs) directed to trophoblast cell surface antigen 2 (TROP2) have gained approval as a therapeutic option for advanced triple‐negative breast cancer, and TROP2 expression has been linked to unfavourable outcomes in various malignancies. In colorectal carcinoma (CRC...
Saved in:
Main Authors: | Sebastian Foersch (Author), Maxime Schmitt (Author), Anne‐Sophie Litmeyer (Author), Markus Tschurtschenthaler (Author), Thomas Gress (Author), Detlef K Bartsch (Author), Nicole Pfarr (Author), Katja Steiger (Author), Carsten Denkert (Author), Moritz Jesinghaus (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2024-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
High expression of insulinoma‐associated protein 1 (INSM1) distinguishes colorectal mixed and pure neuroendocrine carcinomas from conventional adenocarcinomas with diffuse expression of synaptophysin
by: Anne‐Sophie Litmeyer, et al.
Published: (2023) -
Microbiota and Colorectal Cancer: From Gut to Bedside
by: Miguel Silva, et al.
Published: (2021) -
Une femme trop gaie
by: Thierry Savatier
Published: (2003) -
Trop2-targeted therapy in breast cancer
by: Yixuan Hu, et al.
Published: (2024) -
Progress and Innovative Combination Therapies in Trop-2-Targeted ADCs
by: Yizhi Jiang, et al.
Published: (2024)